

SUPPLEMENTAL MATERIAL

1
 2 Supplemental Table 1. Comparison of baseline characteristics in subjects enrolled in AHF trials.
 3 Subjects in ROSE-AHF were less likely to be on ACEi/ARB therapy at baseline, were more
 4 likely to be on sequential nephron blockade as outpatient therapy, and had lower total urine
 5 output during the course of the hospitalization compared to subjects enrolled in DOSE-AHF and
 6 CARRESS-HF.

	DOSE/CARRESS N=379	ROSE N=342	P-Value
Age, years	66 ± 14	70 ± 12	0.001
Male	277 (73)	251 (73)	0.9
Black	91 (24)	69 (20)	0.2
Hypertension	312 (82)	282 (83)	1.0
Diabetes mellitus	214 (57)	188 (55)	0.7
Nonischemic HF etiology	202 (53)	190 (56)	0.5
Ejection Fraction, %	36 ± 18	37 ± 17	0.4
Heart Failure with Preserved Ejection Fraction	110 (30)	107 (32)	0.6
NYHA Class			0.2
• 1-2	10 (3)	16 (5)	
• 3	218 (63)	220 (67)	
• 4	116 (34)	92 (28)	
Medical therapy			
• ACEi/ARB	226 (61)	171 (51)	0.008
• Beta-blocker	309 (83)	283 (84)	0.7
• Aldosterone receptor antagonist	98 (26)	104 (31)	0.2
• Hydralazine	65 (17)	62 (18)	0.7
• Nitrates	118 (32)	84 (25)	0.048

• Digoxin	100 (27)	83 (25)	0.5
• Loop diuretic dose (mg furosemide equivalents)	120 (80, 160)	80 (60, 160)	<0.001
• Sequential nephron blockade	23 (6)	63 (19)	<0.001
Body mass index, kg/m ²	34 ± 10	32 ± 8	0.012
Systolic blood pressure, mm Hg	118 ± 19	117 ± 19	0.5
Diastolic blood pressure, mm Hg	68 ± 14	66 ± 11	0.042
Total urine output, L	11.5 ± 6.0	8.5 ± 3.2	<0.001
Serum chemistries			
• Sodium, mg/dL	138.0 ± 3.8	138.3 ± 3.7	0.5
• Total bilirubin, mg/dL	1.2 ± 0.8	1.1 ± 0.7	0.4
• Blood urea nitrogen, mg/dL	37 (23, 55)	37 (27, 51)	0.3
• Creatinine, mg/dL	1.7 ± 0.6	1.8 ± 0.6	0.1
• eGFR, mL/min/1.72m ²	49 ± 24	43 ± 14	<0.001
• NT-pro BNP (pg/mL)	4,190 (2,193, 9,826)	4,724 (2,330,9,821)	0.3
Days from randomization to discharge	6 (4, 9)	6 (4, 9)	0.4

1

2 Values are mean ± SD, median (interquartile range), or N (%).

Supplemental Table 2. Baseline characteristics of subjects according to race and PRA categories.

	Non-Black, low PRA N=136	Non-Black, high PRA N=136	P-value	Black, low PRA N=40	Black, high PRA N=40	P-value
Age, years	71 ± 11	68 ± 12	0.02	56 ± 14	56 ± 14	0.9
Male	93 (68)	107 (79)	0.05	26 (65)	33 (83)	0.08
Hypertension	107 (79)	112 (82)	0.4	38 (95)	33 (83)	0.1
Diabetes mellitus	81 (60)	79 (58)	0.8	22 (55)	17 (43)	0.3
Ejection Fraction, %	38 ± 18	37 ± 18	0.5	31 ± 16	32 ± 16	0.8
HF with Preserved Ejection Fraction	45 (34)	41 (30)	0.4	9 (22)	8 (21)	0.8
Years since HF diagnosis	6.0 ± 6.6	6.9 ± 7.5	0.3	4.4 ± 4.0	4.1 ± 3.8	0.7
# CV hospitalizations	1.9 ± 1.7	1.7 ± 1.4	0.3	2.7 ± 2.4	2.5 ± 2.8	0.7
# HF hospitalizations	1.5 ± 1.5	1.3 ± 1.3	0.4	2.4 ± 2.3	2.1 ± 1.9	0.5
Medical therapy						
• ACEi/ARB	78 (58)	77 (58)	1.0	31 (78)	23 (58)	0.06
• Beta-blocker	112 (84)	105 (79)	0.3	35 (88)	36 (90)	1.0
• Aldosterone receptor antagonist	19 (14)	46 (35)	<0.0001	11 (28)	16 (40)	0.2
• Hydralazine	15 (11)	13 (10)	0.7	13 (33)	16 (40)	0.5

• Nitrates	39 (29)	37 (28)	0.8	16 (40)	18 (45)	0.7
• Digoxin	23 (17)	42 (32)	0.005	11 (28)	15 (38)	0.3
• Loop diuretic dose (mg furosemide equivalents)	119 ± 78	164 ± 108	<0.0001	111 ± 47	146 ± 81	0.021
• Sequential nephron blockade	3 (2)	15 (11)	0.006	1 (3)	2 (5)	0.6
Body mass index, kg/m ²	33 ± 7	34 ± 11	0.1	38 ± 12	35 ± 11	0.3
Systolic blood pressure, mm Hg	123 ± 20	112 ± 15	<0.0001	132 ± 20	112 ± 15	<0.0001
Diastolic blood pressure, mm Hg	68 ± 15	64 ± 11	0.014	80 ± 16	70 ± 12	0.001
Serum chemistries						
• Sodium, mg/dL	139.5 ± 3.2	136.3 ± 4.1	<0.0001	139.5 ± 2.6	137.3 ± 3.1	0.001
• Potassium, mg/dL	4.0 ± 0.6	4.1 ± 0.6	0.4	3.8 ± 0.5	3.9 ± 0.5	0.2
• Blood urea nitrogen, mg/dL	35 (24, 53)	46 (28, 66)	0.035	24 (13, 43)	33 (16, 50)	0.4
• Creatinine, mg/dL	1.6 ± 0.6	1.7 ± 0.6	0.09	1.5 ± 0.6	1.8 ± 0.6	0.05
• eGFR, mL/min/1.72m ²	49 ± 22	46 ± 21	0.3	67 ± 29	61 ± 31	0.2
• NT-pro BNP (pg/mL)	4,441 (2,453, 12,095)	4,072 (2,267, 8,781)	0.2	4,558 (2,212, 11,331)	2,636 (1,293, 8,440)	0.2
Days from randomization to discharge	6.9 ± 7.0	9.7 ± 9.2	0.009	6.9 ± 6.5	8.3 ± 6.7	0.4

